Biose Industrie

About Biose Industrie

The story of Biose Industrie begins in 1951, when a group of pharmacists and microbiologists in Aurillac, France, founded the company, then known as Laboratoires Lyocentre. For decades, it specialized in producing drugs from living bacteria. A key turning point came in 1997 when Hubert Desjonquères acquired the company, revitalizing its industrial and commercial focus. His son, Stanislas Desjonquères, took over as CEO in 2007, continuing to build on this foundation. The company carved out a niche as a Contract Development and Manufacturing Organization, or CDMO, for biotech and pharmaceutical firms. Essentially, Biose Industrie became the go-to partner for developing and manufacturing Live Biotherapeutic Products (LBPs), the complex therapeutics derived from the human microbiome. This specialization proved to be a powerful growth engine, attracting international clients, particularly from the United States. A major event in the company's journey occurred in February 2023. In a deal valued at €80 million, private equity firm L-GAM and the French State, through its "French Tech Souveraineté" fund, acquired joint control of Biose Industrie. This investment was not a typical acquisition but a strategic partnership to fuel the company's next growth phase, allowing it to expand its production capacity, hire hundreds of new employees, and solidify its global leadership in the burgeoning field of microbiome therapeutics.